Dissolution Testing of new and special Dosage Forms - Updated FIP/AAPS Document
![Stability Studies to Support Shipping/Distribution of Pharmaceuticals and Biopharmaceuticals - Live Online Training](files/eca/userImages/training.img/Z-ECA-Stability-Studies-Shipping-Distribution-LOT.jpg)
Recommendation
12/13 September 2024
In 2003, the FIP Dissolution Working group published a position paper on dissolution/drug release testing for special and novel dosage forms that represented the scientific knowledge in the field at that time. This position paper from 2003 has given impetus in the scientific, technical, and regulatory community.
Due to the rapid evolution of new practices and techniques for dissolution/drug release testing, the FIP Special Interest Group on Dissolution/Drug Release decided to revise the previous paper.
In the recently presented Workshop Report the following dosage forms are discussed:
- Conventional solid drug products
- Oral suspensions
- Orally disintegrating tablets
- Chewable tablets
- Powders and granules
- Thin dissolvable films
- Chewing gums
- Dermal systems (patches)
- Topical systems (semisolid dosage forms)
- Suppositories
- Microparticulate formulations
- Implants
- Aerosols
Please find the extensive Report at "FIP/AAPS Joint Workshop Report: Dissolution/In Vitro Release Testing of Novel/Special Dosage Forms".
Author:
Dr. Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
24.07.2024FDA Warning Letter to Chinese OTC Manufacturer for Lack of Analytical Test Data
10.07.2024Pharmeuropa: Two Revised Chapters on Dissolution Testing published for comments
03.07.2024FDA Warning Letter: GMP Requirements also apply to HPLC Analyses for Internal Use
12.06.2024NMPA Announcement on Application of ICH Q2(R2) and Q14 Principles
22.05.2024Q&As from the Live Online Training "Introduction to the AQCG's new AIQSV Guide" - Part 1
22.05.2024FDA Warning Letter to Contract Testing Laboratory in Uruguay due to Data Integrity Violations